Cargando…

2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint

AIM: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (W...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhiyi, Huang, Cibo, Cao, Yongping, Mu, Rong, Zhang, Mun Chan, Xing, Dan, Fan, Dongwei, Ding, Yunpong, Guo, Junhuan, Hou, Yong, Jianhao, Lin, Veronese, Nicola, Reginster, Jean-Yves, Bruyere, Olivier, Cavalier, Etienne, Zhang, Huaihuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302513/
https://www.ncbi.nlm.nih.gov/pubmed/34189714
http://dx.doi.org/10.1007/s40520-021-01906-y
_version_ 1783726895318171648
author Zhang, Zhiyi
Huang, Cibo
Cao, Yongping
Mu, Rong
Zhang, Mun Chan
Xing, Dan
Fan, Dongwei
Ding, Yunpong
Guo, Junhuan
Hou, Yong
Jianhao, Lin
Veronese, Nicola
Reginster, Jean-Yves
Bruyere, Olivier
Cavalier, Etienne
Zhang, Huaihuan
author_facet Zhang, Zhiyi
Huang, Cibo
Cao, Yongping
Mu, Rong
Zhang, Mun Chan
Xing, Dan
Fan, Dongwei
Ding, Yunpong
Guo, Junhuan
Hou, Yong
Jianhao, Lin
Veronese, Nicola
Reginster, Jean-Yves
Bruyere, Olivier
Cavalier, Etienne
Zhang, Huaihuan
author_sort Zhang, Zhiyi
collection PubMed
description AIM: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (WG), including ESCEO members and Chinese experts, wished to see how the new ESCEO algorithm was perceived by Chinese experts in knee OA and how it was integrated into their clinical practice. METHODS: A WG was held between members of the international ESCEO task force and a group of Chinese experts. RESULTS: Non-pharmacological approach should be combined with pharmacological interventions. In step 1, symptomatic slow-acting drugs for osteoarthritis (SYSADOA) are the most important background drugs. Evidence, supported by high-quality research, is available only for crystalline glucosamine sulfate (pCGS) and chondroitin sulfate. Topical NSAIDs could be used as an additional option. In step 2, oral NSAIDs could be useful, but cardiovascular/renal/gastrointestinal profiles of the patients should be considered. Intra-articular hyaluronic acid and corticosteroids are alternative to oral NSAIDs, but the evidence is still limited. If steps 1 and 2 are not sufficient, weak opioids could be used. Overall, the conclusions of the ESCEO algorithm are accepted in China for products available in this country. The WG suggests the importance of economic studies, specifically made in China. CONCLUSION: This work provides evidence-based advice to establish a treatment algorithm in knee OA, for practical implementation in clinical practice in China.
format Online
Article
Text
id pubmed-8302513
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83025132021-07-27 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint Zhang, Zhiyi Huang, Cibo Cao, Yongping Mu, Rong Zhang, Mun Chan Xing, Dan Fan, Dongwei Ding, Yunpong Guo, Junhuan Hou, Yong Jianhao, Lin Veronese, Nicola Reginster, Jean-Yves Bruyere, Olivier Cavalier, Etienne Zhang, Huaihuan Aging Clin Exp Res Consensus Document AIM: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (WG), including ESCEO members and Chinese experts, wished to see how the new ESCEO algorithm was perceived by Chinese experts in knee OA and how it was integrated into their clinical practice. METHODS: A WG was held between members of the international ESCEO task force and a group of Chinese experts. RESULTS: Non-pharmacological approach should be combined with pharmacological interventions. In step 1, symptomatic slow-acting drugs for osteoarthritis (SYSADOA) are the most important background drugs. Evidence, supported by high-quality research, is available only for crystalline glucosamine sulfate (pCGS) and chondroitin sulfate. Topical NSAIDs could be used as an additional option. In step 2, oral NSAIDs could be useful, but cardiovascular/renal/gastrointestinal profiles of the patients should be considered. Intra-articular hyaluronic acid and corticosteroids are alternative to oral NSAIDs, but the evidence is still limited. If steps 1 and 2 are not sufficient, weak opioids could be used. Overall, the conclusions of the ESCEO algorithm are accepted in China for products available in this country. The WG suggests the importance of economic studies, specifically made in China. CONCLUSION: This work provides evidence-based advice to establish a treatment algorithm in knee OA, for practical implementation in clinical practice in China. Springer International Publishing 2021-06-29 2021 /pmc/articles/PMC8302513/ /pubmed/34189714 http://dx.doi.org/10.1007/s40520-021-01906-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Consensus Document
Zhang, Zhiyi
Huang, Cibo
Cao, Yongping
Mu, Rong
Zhang, Mun Chan
Xing, Dan
Fan, Dongwei
Ding, Yunpong
Guo, Junhuan
Hou, Yong
Jianhao, Lin
Veronese, Nicola
Reginster, Jean-Yves
Bruyere, Olivier
Cavalier, Etienne
Zhang, Huaihuan
2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint
title 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint
title_full 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint
title_fullStr 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint
title_full_unstemmed 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint
title_short 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint
title_sort 2021 revised algorithm for the management of knee osteoarthritis—the chinese viewpoint
topic Consensus Document
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302513/
https://www.ncbi.nlm.nih.gov/pubmed/34189714
http://dx.doi.org/10.1007/s40520-021-01906-y
work_keys_str_mv AT zhangzhiyi 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT huangcibo 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT caoyongping 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT murong 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT zhangmunchan 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT xingdan 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT fandongwei 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT dingyunpong 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT guojunhuan 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT houyong 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT jianhaolin 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT veronesenicola 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT reginsterjeanyves 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT bruyereolivier 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT cavalieretienne 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint
AT zhanghuaihuan 2021revisedalgorithmforthemanagementofkneeosteoarthritisthechineseviewpoint